Hanmi Pharm Co Ltd 2022 SR
The report highlights Hanmi Pharm's 2021 performance, including record revenues of KRW 1.2032 trillion and a significant R&D investment of KRW 161.5 billion. Key achievements include maintaining the top spot in the domestic outpatient prescription market for four consecutive years and receiving the first Korean approval for the new bio drug Rolontis. The company became the first in Korea to achieve a 'AAA' grade in the Fair Trade Commission's Compliance Program. Sustainability efforts are underscored by joining the UN Global Compact and achieving a 24.4% reduction in greenhouse gas emissions.
Company: Hanmi Pharm Co Ltd
Sector: Health Care
Country: South Korea
Year: 2022
Type: SR
Pages: 56
Hanmi Pharm Co Ltd
CSR Report
The report highlights Hanmi Pharm's 2021 performance, including record revenues of KRW 1.2032 trillion and a significant R&D investment of KRW 161.5 billion. Key achievements include maintaining the top spot in the domestic outpatient prescription market for four consecutive years and receiving the first Korean approval for the new bio drug Rolontis. The company became the first in Korea to achieve a 'AAA' grade in the Fair Trade Commission's Compliance Program. Sustainability efforts are underscored by joining the UN Global Compact and achieving a 24.4% reduction in greenhouse gas emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
May 1, 2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees